The change to open listing on the NL Prescription Drug Program reduces the administrative burden of prescribers by eliminating the special authorization process that had been in place.
Government is expanding prescription coverage for long-acting muscarinic antagonist (LAMAs) inhalers, used in the treatment of Chronic Obstructive Pulmonary Disease. The change to open listing on the NL Prescription Drug Program reduces the administrative burden of prescribers by eliminating the special authorization process that had been in place. This will ensure NLPDP beneficiaries have timely access to these inhalers for the treatment of their COPD.
Premier-designate Tony Wakeham announces transition team
Family plans weekend fireworks sendoff in honour of former Stephenville Mayor Tom O'Brien
2026 NL Summer Games in Corner Brook looking for directors on Host Committee
Female pedestrian in Ship Cove dies after being struck by an ATV, RCMP say the operator was a youth
St. John's driver clocked doing 207 km/hr on the TCH near Pasadena
